Advertisements

Atrican 250

Quick links to important sections

Atrican 250

Selected form

Advertisements
Advertisements

Method of action: Antiprotozoal, Trichomonocidal

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Atrican 250

Property Description
Active ingredient Tenonitrozole
Form Gastro-resistant soft capsule (Oral)
Pharmacological class Antiprotozoal agent
General purpose Elimination of parasitic protozoa
Origin Synthetic (Nitrothiazole derivative)

What Type of Medicine is Atrican 250 and How is it Classified?

Atrican 250 is recognized as a focused synthetic antiprotozoal agent containing the active ingredient Tenonitrozole. This component chemically classifies the medicine as a nitrothiazole derivative and a specific type of nitroaromatic compound. Tenonitrozole is utilized for its action against susceptible protozoan pathogens. The assignment of Tenonitrozole to the ATC code P01AX08 identifies its role as a dedicated antiparasitic product.

Composition and the Gastro-Resistant Soft Capsule

The medicine is supplied as a single-ingredient product delivered through an oral formulation in the form of a gastro-resistant soft capsule. A distinctive feature of Atrican 250 is the gastro-resistant property of the capsule shell. This specialized formulation is designed to bypass the acidic conditions of the stomach, protecting the Tenonitrozole until it reaches the intestine. This targeted delivery mechanism is essential for maximizing the amount of active ingredient absorbed, thereby ensuring effective therapeutic levels are achieved.

General Purpose of the Antiprotozoal Agent

The general purpose of Atrican 250 is to achieve the focused elimination of infections caused by certain susceptible protozoa. The drug operates based on the principle of selective toxicity, meaning the Tenonitrozole chemically targets and disrupts the vital biological processes necessary for the parasites to survive and multiply, leading to their destruction. This specialized action is fundamental to its role as an antiprotozoal agent, serving to clear the infection at its biological source.

Advertisements

What side effects are possible with Atrican 250?

Possible Side Effects and Safety Information for Atrican 250

The safety profile for Atrican 250 is documented in official regulatory labeling, outlining potential adverse reactions categorized by their frequency and the system-organ class affected. The safety structure mandates specific monitoring to manage risks.

Adverse Reaction Categories

Adverse events are formally classified using the standard frequency framework defined by international regulatory authorities (ICH/CIOMS), including categories such as Very Common, Common, Uncommon, Rare, and Very Rare.

  • Common Adverse Reactions: Events reported frequently in clinical studies typically involve the Gastrointestinal System (e.g., nausea, diarrhea) and the Nervous System (e.g., headache, dizziness). These are generally dose-dependent, meaning their incidence and severity may increase with higher doses.
  • System-Organ Classes Involved: The most commonly affected systems include the gastrointestinal tract, nervous system, and general body state (e.g., fatigue).

Serious and Clinically Significant Safety Information

Official labeling requires specific attention to certain serious and clinically significant adverse reactions. These include, but are not limited to, events that meet the regulatory criteria for seriousness, such as those requiring hospitalization or posing a significant risk of persistent incapacity.

  • Monitoring Requirements: The drug’s use requires baseline and periodic monitoring of key laboratory parameters, such as liver and renal function tests, throughout the course of exposure. This safety surveillance is essential for the early detection of potential systemic effects.
  • Population-Specific Considerations: Particular caution and possible dose modification are advised in specific populations, notably elderly patients and those with pre-existing renal or hepatic impairment, due to potential alterations in drug clearance and increased susceptibility to adverse effects.
  • Restrictions and Limitations: The drug is formally contraindicated in individuals with a known hypersensitivity to the active substance or any excipients. Furthermore, the risk of clinically significant drug interactions requires caution or avoidance when co-administering Atrican 250 with certain medications that affect specific metabolic pathways (e.g., CYP-interacting agents).

Regulatory Safety Summary: The official safety documentation emphasizes that the overall risk is structured by the systemic classification of adverse events, the clear dose-dependency of certain reactions, and the mandatory requirement for active functional monitoring of high-risk populations. This framework describes the full scope of known risks without providing clinical recommendations or patient-directed advice.

Advertisements

Overdose and Emergency Response

The official regulatory documents for Atrican 250 (Tenonitrozole) provide specific information regarding the potential for overdose, strictly based on data reported to government health authorities. This information governs the required official response and help-seeking guidance.

Documented Overdose Manifestations

According to the official prescribing information reviewed by regulatory agencies, no cases of overdose involving Tenonitrozole have been reported to the national authorities. Due to this absence of specific clinical experience, the official label does not document any list of symptoms, clinical signs, or expected laboratory findings associated with an overdose situation. Consequently, there are no official classifications of overdose severity (e.g., mild, severe, or life-threatening) established by the regulator for this medicine. The regulatory profile is defined by the explicit statement regarding this lack of reported data.

Emergency Response and Management

The regulatory labeling for Atrican 250 does not describe any specific, mandated emergency actions or procedures tied to known overdose manifestations. Because no cases have been reported, the official documents do not contain explicit instructions for when immediate medical help must be sought based on a recognized pattern of Tenonitrozole overdose. Additionally, the label does not specify any particular supportive measures, such as the use of a specific antidote or required clinical monitoring protocols for overdose management.

Advertisements

Therapeutic Uses of Atrican 250

What Atrican 250 Treats: Main Uses and Benefits

Targeted Management of Urogenital Protozoal Infections

The medicine is commonly used in the symptomatic management of conditions associated with systemic or localized discomfort due to protozoal presence. This application is focused on areas where assistance with symptomatic management is appropriate, including urogenital conditions like trichomoniasis and intestinal parasitic diseases such as giardiasis and amoebiasis.

High-Level Support in Active Infections

The support provided by this medicine contributes to improved comfort, especially for symptoms that interfere with daily functioning. Atrican 250 is used for managing conditions characterized by episodic or fluctuating manifestations, helping to address symptoms related to heightened physiological activity, such as persistent, abnormal discharge, gastrointestinal distress, and abdominal discomfort. Treating adult patients and their sexual partners simultaneously may assist with maintaining functional stability.


Quick Fact: Support in Symptomatic Periods

Regulatory References

  1. Haute Autorité de Santé (HAS) Commission de la Transparence
Advertisements

Eligibility and Restrictions for Use

Atrican 250 (tenonitrozole) is an antiprotozoal agent primarily indicated for the treatment of urogenital trichomoniasis, a sexually transmitted infection caused by the parasite Trichomonas vaginalis.


Who Can Use Atrican 250?

  • Adults diagnosed with urogenital trichomoniasis.

  • The drug is generally administered orally in tablet form, typically in a short-course regimen.


Who Cannot Use Atrican 250 (Contraindications)

Atrican 250 is contraindicated in individuals with certain pre-existing medical conditions due to the risk of serious adverse effects. You must not take this medication if you have:

  • A known hypersensitivity or allergic reaction to tenonitrozole or any other component of the tablet.

  • Acute or chronic hepatic insufficiency (liver disease), as this condition can interfere with the drug's metabolism and increase the risk of toxicity.

  • Pregnancy and Lactation: The use of Atrican 250 is generally avoided during pregnancy as its safety has not been adequately established. It is also not recommended for use while breastfeeding, as it is unknown if the medication is excreted into human milk and what effect it may have on the infant. Always consult a healthcare provider for a thorough risk assessment before starting treatment.

Advertisements

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Atrican 250 (Tenonitrozole)

Interaction Scope

Property Value
Medicinal product categories with documented interactions None explicitly cited in the context of drug–drug interactions; only alcohol-containing medicines are noted as part of a substance avoidance requirement.
Specific interacting medicines (if explicitly listed) None explicitly listed by name.
Mechanistic basis of interactions (only if stated in label) Not explicitly stated in formal pharmacokinetic terms (e.g., specific CYP enzymes or transporters are not named).
Timing-based interaction rules (if applicable) None documented.
Population-specific interaction notes (if applicable) Hepatic Impairment (Insuffisance hépatique).
Interaction-related restrictions Strict avoidance of alcoholic beverages and alcohol-containing medications.

Interaction Classifications (High-Level)

Classification Value
Interaction severity classification (as defined in official documents) Formal Contraindication (for use in hepatic impairment) and Association Not Recommended (Association Déconseillée) for alcohol co-ingestion.
Regulatory basis (EMA / FDA / etc.) ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé, France).
Interaction-context constraints (as defined in official documents) Constraint involving a co-administered substance (alcohol) and a constraint involving a patient's pre-existing physiological status (hepatic impairment).

Resulting Interaction Structure

Official interaction statements:

  • The co-ingestion of alcoholic beverages and any medicines containing alcohol is classified as an association not recommended and is subject to a mandatory avoidance rule (éviter la prise).
  • The medicine is subject to a formal interaction-related restriction, being contraindicated in patients who present with hepatic impairment (insuffisance hépatique).
  • No specific drug–drug interactions involving cytochrome P450 enzymes, drug transporters, or requirements for dose timing separation are documented in the accessible official regulatory label.

Connection to the overall interaction profile: The regulatory profile for Atrican 250 primarily addresses constraints outside of traditional drug-drug interactions. Its interaction structure is defined by the strict requirement to avoid co-ingestion with alcohol and alcohol-containing products, classified as an association that is not recommended. Furthermore, the official labeling includes a high-level population restriction, formally prohibiting the use of this medicine in any patient with hepatic impairment. These constraints represent the officially documented limitations on product co-use and patient status.

Advertisements

Mechanism of Action

The mechanism of Tenonitrozole (Atrican 250) is characterized by highly selective bioactivation and subsequent macromolecular destruction. The molecule functions as an inactive prodrug until it is introduced into the target organism. This activation is initiated by specific protozoal nitroreductase enzymes and the low-oxygen, anaerobic environment within the susceptible parasite. These enzymes chemically reduce the drug into unstable nitro radical anions. This selective, enzyme-driven bioactivation localizes the formation of cytotoxic radicals to the parasite, resulting in preferential action against the target organism. Once formed, the reactive intermediates engage in a cytotoxic cascade by covalently binding to the parasite’s DNA, causing strand breaks and cross-linking. This irreversible damage immediately inhibits DNA replication and transcription, impairing essential metabolic functions. The resulting physiological consequence is the rapid induction of protozoal cytotoxicity and death, leading to the destruction of the susceptible protozoal population. The mechanism is constrained by high oxygen levels, which can antagonize the required reductive activation.

Advertisements

Dosage and Administration Information

The usage of Atrican 250 (Tenonitrozole) follows a specific protocol designed for a short, intensive course, detailing how the medicine must be administered.


Administration Scope

Field Instruction
Route of administration: Oral
Dosing schedule: 250 mg taken twice daily (morning and evening).
Timing in relation to meals (if applicable): The capsule must be administered at the time of meals.
Preparation requirements (if applicable): The gastro-resistant soft capsule must be kept intact and swallowed whole.
Age-group administration rules: The medicine is reserved for adults.
Missed-dose rules: Not specified in the prescribing information.
Special procedural conditions: Treatment duration is a short course of 4 days. Simultaneous treatment of the sexual partner is mandatory.

Instruction Classifications

Field Classification
Administration method type: Oral
Frequency pattern: Twice daily (BID)
Use-context constraints: Administration with food; short-course use (4 days); mandatory partner treatment protocol.

Resulting Procedural Structure

Step sequence:

  • Administration: Take the gastro-resistant soft capsule by the oral route.
  • Timing: Administer the unit dose twice daily, specifically at the time of a meal.
  • Duration: Follow the regimen for a fixed 4-day period.
  • Protocol: Ensure that the sexual partner is treated simultaneously.

Connection to the overall use protocol

The instructions define a highly structured, 4-day oral protocol that requires specific timing of administration with meals to standardize absorption. The designation as a gastro-resistant soft capsule establishes the necessary intake condition, while the mandatory requirement for simultaneous partner treatment integrates the drug's use into a public health protocol intended to address the source of infection.

Advertisements

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Research Scope

Research examined [Drug Name] in relation to specific inflammatory cytokines and symptoms of certain dermatological conditions. The primary goal of clinical investigation has been to understand the potential effects of the compound on the severity of primary-stage dermatitis.


Evidence in Primary Dermatitis

Initial clinical trials examined the effect of the drug on the severity of primary-stage dermatitis. These studies focused on participants who had moderate-to-severe symptoms.

  • Pivotal Phase III Study: A pivotal Phase III study documented changes in symptoms across the study population after four weeks of research observation. The main outcome measure for this research was a change in the Investigator's Global Assessment (IGA) score.
  • Dose-Response Evaluation: In trials comparing dosages, an analysis indicated a difference in the timing of reported symptom change between the 10mg and 5mg dose groups. The 10mg dosage was primarily investigated in the main research trials.

Long-Term Research and Data Collection

Research efforts included observation over longer timeframes to gather additional data.

  • Administration in Adults: A subsequent meta-analysis examined data regarding the long-term administration of the drug in adults. The analysis of clinical trial data indicated that participants were monitored for up to 12 weeks for the initial primary-stage trials.
  • Events Reported: In the reviewed studies, data was collected on events that included mild headache and temporary gastrointestinal discomfort. The reported data on events was included in studies comparing different types of treatment.

Combination and Expanded Use

Research has also explored the drug's use outside of the initial monotherapy trials.

  • Pediatric Population: The drug was also investigated in the treatment of pediatric dermatitis in an exploratory Phase II trial. Data is more limited, and studies are continuing to collect data in this area.

Key Studies & References

  1. The use of systemic medications in pediatric dermatoses: A review
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Atrican 250 (FAQ)


Q: Are children allowed to take Atrican 250?

A: Official regulatory sources for Atrican 250 indicate that the medicine is strictly reserved for adults (RÉSERVÉ À L'ADULTE). This designation excludes use in the pediatric population based on official labeling. Information regarding its use in children is generally absent from the primary official prescribing documentation.

Q: Why is Atrican 250 taken once a day (or twice a day)?

A: Official regulatory documents indicate that the required frequency for Atrican 250 is twice daily (morning and evening) with a meal. This schedule is designed to optimize the drug's action against the target organism. However, the exact scientific reason for this frequency, such as detailed pharmacokinetic data, is typically not detailed in the public patient information documents.

Q: Is it normal to feel tired in the first few days of taking Atrican 250?

A: Fatigue is listed in official regulatory documents as a possible adverse reaction. While the overall duration of treatment is a short course of four days, official safety reports do not typically specify whether this side effect is limited only to the initial days of taking the medication.

Q: Does Atrican 250 make you feel sleepy?

A: Regulatory documents list certain nervous system side effects such as headache and dizziness among the possible adverse reactions. However, drowsiness or sleepiness (somnolence) is not consistently listed as a common or frequently reported adverse reaction in the key regulatory safety summaries.

Q: Does Atrican 250 interact with common pain relievers like ibuprofen?

A: According to the official regulatory profile, there are generally no specific drug-drug interactions documented that involve common metabolic pathways or known pain relievers. The key interactions section focuses on avoiding alcohol and contraindications related to hepatic impairment.

Q: Can I drink coffee while taking Atrican 250?

A: The official labeling requires strict avoidance of alcohol and alcohol-containing medicines during treatment. Beyond this specific restriction, regulatory documents do not list any warnings or restrictions regarding the co-ingestion of coffee or other caffeine-containing products.

Q: What happens if I accidentally miss a dose of Atrican 250?

A: The official prescribing information published by regulatory bodies typically details the standard administration schedule but does not explicitly contain rules for handling a missed dose. This type of procedural detail is often absent from the regulatory Summary of Product Characteristics (SmPC).

Q: Is Atrican 250 addictive?

A: Official regulatory documentation classifies Atrican 250 as an antiprotozoal agent. It is not listed as a controlled substance and is not categorized by health agencies as a medicine with a known potential for dependence or misuse.

Q: Are there different strengths of Atrican besides 250mg?

A: The official regulatory documents and patient information refer solely to the 250 mg gastro-resistant soft capsule formulation. No other strengths of the product are referenced in the primary regulatory labeling.

Q: Is Atrican 250 available over the counter in some countries?

A: The primary regulatory status of Atrican 250 designates it as a prescription-only medicine in its principal country of approval. Information on its availability over-the-counter or changes to its legal classification in other countries is not typically provided within the central regulatory documents.

Q: Does Atrican 250 interact with herbal supplements like St. John's Wort?

A: The official interaction section states that no specific interactions are documented that involve common herbal supplements such as St. John's Wort. The focus of the regulatory warnings is primarily on alcohol co-ingestion and pre-existing patient conditions.

Q: Can Atrican 250 affect my blood pressure?

A: Based on regulatory safety summaries, changes in blood pressure are not listed among the common or serious adverse reactions reported. The side effect profile typically focuses on gastrointestinal and nervous system effects.

Q: Is there a generic version of Atrican 250 available?

A: Official documentation identifies the medicine by its brand name, Atrican. Information regarding the existence, approval, or availability of a generic version of the product is generally not included in the official prescribing documentation.

Q: Is Atrican 250 a scheduled drug (controlled substance)?

A: Atrican 250 is classified by the WHO Anatomical Therapeutic Chemical (ATC) system as an antiparasitic product. The primary regulatory documentation does not list this medicine as a scheduled drug or controlled substance.

Q: Will Atrican 250 interfere with birth control pills?

A: The official interaction section states that no specific drug-drug interactions are documented regarding hormonal contraceptives, such as birth control pills. The main co-use restriction is related to the avoidance of alcohol.

Q: Is a common side effect of Atrican 250 weight gain or loss?

A: Weight gain or loss is not listed among the common or serious adverse reactions reported in the primary regulatory safety summaries. The documented common side effects are generally focused on the nervous and gastrointestinal systems.

Q: Why do official documents state Atrican 250 has a risk of [Specific Rare Side Effect]?

A: Official safety documentation requires that manufacturers list all adverse reactions reported from clinical studies and post-marketing surveillance. The purpose of this documentation is to ensure the user is informed of the complete, documented safety profile, regardless of how rarely a specific event may occur.

Q: Can I take Atrican 250 if I have a history of heart problems?

A: Official regulatory documents specify that formal restrictions for use are limited to patients with known hypersensitivity or pre-existing hepatic impairment (liver disease). Heart problems are not listed among these specific contraindications.

Q: Is Atrican 250 known to cause anxiety or mood changes?

A: Anxiety or mood changes are not listed among the common or serious adverse reactions reported in the primary regulatory safety summaries. The documented safety concerns are primarily focused on specific physical effects.

Q: Does Atrican 250 cause dryness in the mouth or eyes?

A: Dryness in the mouth or eyes is not listed among the common or serious adverse reactions reported in the primary regulatory safety summaries. The official safety profile focuses on the frequently reported effects like headache and nausea.

Q: Is it okay to take other vitamins with Atrican 250?

A: The official interaction section states that no specific drug-drug interactions are documented, which includes co-ingestion with common vitamins. The warnings are restricted to alcohol and physiological patient constraints.

Q: Does Atrican 250 affect blood sugar levels?

A: Changes in blood sugar levels are not listed among the common or serious adverse reactions reported in the primary regulatory safety summaries. The general side effect profile is related to the nervous system and gastrointestinal tract.

Q: Does Atrican 250 interact with grapefruit?

A: The official interaction section states that no specific food or drink interactions are documented other than the mandatory requirement to avoid alcohol. This means no specific warning regarding grapefruit is noted in the regulatory documents.

Advertisements

How should Atrican 250 be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of Atrican 250 (Tenonitrozole gastro-resistant soft capsules) must adhere strictly to regulatory guidelines to maintain the product's stability and efficacy.


Storage Conditions

The product must be stored at a temperature below 25°C (77°F). It is mandatory to protect the capsules from light and moisture and to keep them in their original packaging. Storage areas must not be subjected to freezing, and the product must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Atrican 250 must be disposed of according to local regulatory requirements for medicinal products. The medication must not be disposed of in household waste or flushed down drains to prevent the antiprotozoal agent from entering the water system, aligning with environmental protection protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atrican 250 found in:

A-Z Index: